MORRISTOWN, N.J., July 2 /PRNewswire-FirstCall/ — Watson
Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson
Laboratories, Inc., has received approval from the United States
Food and Drug Administration on its Abbreviated New Drug
Application (ANDA) for Tacrolimus 5 mg capsules, the generic
equivalent to Astellas’ Prograf® capsules. Watson intends to
begin shipping the product immediately.
Prograf ® 5 mg had total U.S. sales of approximately $108 million for the twelve months ending
May 2010, according to IMS Health.
Tacrolimus capsules are indicated for the prophylaxis of
organ rejection in patients receiving allogeneic liver, kidney, or
heart transplants.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is a leading global specialty
pharmaceutical company. The Company is engaged in the
development and distribution of generic pharmaceuticals and
specialized branded pharmaceutical products focused on Urology and
Women’s Health. Watson has operations in many of the world’s
established and growing international markets.
For press release and other company information, visit Watson
Pharmaceuticals’ Web site at http://www.watson.com.
Forward-Looking Statement
Statements contained in this press release that refer to
non-historical facts
‘/>”/>
SOURCE
